EAU 2017 | The role of Radium 223 in metastatic castration resistant prostate cancer

Kurt Miller, MD, PhD, from Charité University Hospital, Berlin, Germany, discusses the role of Radium-223 in prostate cancer at the European Association of Urology (EAU) conference in 2017 in London, UK. Radium-223 has been used in the treatment of metastatic castration resistant prostate cancer in the past couple of years. In a recent iEAP, Radium-223 combined with abiraterone or enzalutamide (NCT02034552) was shown to have a significant survival advantage. There is currently a phase 3 study comparing the combination of abiraterone with Radium-223 to abiraterone alone (NCT02043678). The results of the study have not yet been released, but if they are positive, this would also have an impact on daily clinical practice.